Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Summary

This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis. This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.

Timeline

Start

2019-04-22

Primary completion

2020-05-18

Completion

2020-07-31

Outcome

Outcome not reported

Stopped: “to carry out the rest of the study with new CRO and modified protocol as a multi-regional study.”

Drugs

Indications